Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Added

TDQS

A4.9/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Discloses rich behavioral details beyond annotations: pulls from SEC EDGAR/XBRL for companies (including off-calendar fiscal year handling), FAERS/FDA data for drugs, sorts by primary metric, and returns paired data with citation URIs. Annotations (readOnlyHint, idempotentHint) are consistent and the description adds valuable context about data provenance and output ordering.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense but every sentence adds value—trigger phrases, data sources, fiscal year edge case, sorting, and return format. It could be tightened slightly (e.g., the 'ALWAYS PREFER' and 'Replaces 8–15' statements overlap), but remains well-organized and front-loaded with the primary purpose.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a 2-parameter tool with no output schema, the description is remarkably complete: it explains inputs (types, value formats), outputs (paired data, citation URIs), sorting behavior, data sources, and edge cases (off-calendar fiscal years). It fully compensates for the missing output schema and stands out among siblings like entity_profile.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema already covers 100% of parameters, but the description adds significant meaning: it explains what 'type' values pull (10-K metrics vs FAERS counts) and what 'values' arrays expect (tickers/CIKs vs drug names with examples). This goes well beyond the schema's basic enum/item descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description explicitly states the tool's purpose: 'side-by-side comparison of 2–5 companies or drugs in ONE parallel call' with a specific verb and resource. It distinguishes from siblings by emphasizing it replaces sequential single-pack lookups, and the trigger phrases ('X vs Y', 'which is bigger') make the intent unmistakable.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Clear when-to-use guidance: 'ALWAYS PREFER over sequential single-pack lookups when comparing entities' and 'Replaces 8–15 sequential lookups' explicitly contrast with alternatives. Type-specific guidance for company vs drug data sources further clarifies scenarios.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation4/5

Most tools have clear distinct purposes, but ask_pipeworx, ask_pipeworx_grounded, and deep_research overlap in querying Pipeworx data sources. Entity_profile and recent_changes also share some coverage. Overall, agents can differentiate, but a few pairs may cause confusion.

Naming Consistency3/5

Tool names use snake_case for multi-word (e.g., ai_visibility_check) but also single-word verbs (forget, recall, remember). The pattern is not uniform: some are verb_noun, some are just noun or verb. Mixed conventions reduce predictability.

Tool Count3/5

At 33 tools, the set is on the high side for an MCP server. The server covers a broad data-query domain, which justifies many specialized tools, but the count is borderline heavy and includes several meta-tools (discover_tools, suggest_questions). Could be streamlined without losing core functionality.

Completeness4/5

The tool surface is comprehensive for data retrieval across financial, economic, pharmaceutical, real estate, weather, and prediction markets. It includes both single-lookup and comparative tools, plus monitoring via subscriptions. Minor gaps exist (e.g., no direct update/delete for user memory beyond forget), but the core domain is well-covered.